Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities

被引：339

作者：

Balachandran, Vinod P. ^{[1
]}

Beatty, Gregory L. ^{[2
,3
]}

Dougan, Stephanie K. ^{[4
,5
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Surg, David M Rubenstein Ctr Pancreat Canc Res, Hepatopancreatobiliary Serv,Parker Inst Canc Immu, 1275 York Ave, New York, NY 10021 USA

[2] Univ Penn, Abramson Canc Ctr, Perelman Ctr Adv Med South Tower SPE 8,Room 8-107, Philadelphia, PA 19104 USA

[3] Univ Penn, Dept Med, Perelman Sch Med, Div Hematol Oncol, Philadelphia, PA 19104 USA

[4] Dana Farber Canc Inst, Dept Canc Immunol & Virol, Boston, MA 02115 USA

[5] Harvard Med Sch, Dept Immunol, Boston, MA 02115 USA

来源：

GASTROENTEROLOGY | 2019年 / 156卷 / 07期

基金：

美国国家卫生研究院;

关键词：

PDAC; Immunity; Clinical Trials; Immunotherapy; Pancreatic Cancer; REGULATORY T-CELLS; TUMOR-INFILTRATING MACROPHAGES; SUPPRESSOR-CELLS; ONCOGENIC KRAS; TGF-BETA; DUCTAL ADENOCARCINOMA; CHEMOTHERAPY EFFICACY; ANTITUMOR IMMUNITY; PHYSICAL BARRIERS; RECEPTOR BLOCKADE;

D O I：

10.1053/j.gastro.2018.12.038

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Pancreatic ductal adenocarcinoma (PDAC) is projected to become the second deadliest cancer in the United States by 2025, with 5-year survival at less than 10%. In other recalcitrant cancers, immunotherapy has shown unprecedented response rates, including durable remissions after drug discontinuation. However, responses to immunotherapy in PDAC are rare. Accumulating evidence in mice and humans suggests that this remarkable resistance is linked to the complex, dueling role of the immune system in simultaneously promoting and restraining PDAC. In this review, we highlight the rationale that supports pursuing immunotherapy in PDAC, outline the key barriers that limit immunotherapy efficacy, and summarize the primary preclinical and clinical efforts to sensitize PDAC to immunotherapy.

引用

页码：2056 / 2072

页数：17

共 173 条

[1] Development of a T Cell Receptor Targeting an HLA-A*0201 Restricted Epitope from the Cancer-Testis Antigen SSX2 for Adoptive Immunotherapy of Cancer [J].

Abate-Daga, Daniel ;

Speiser, Daniel E. ;

Chinnasamy, Nachimuthu ;

Zheng, Zhili ;

Xu, Hui ;

Feldman, Steven A. ;

Rosenberg, Steven A. ;

Morgan, Richard A. .

PLOS ONE, 2014, 9 (03)

[2] A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer [J].

Aglietta, M. ;

Barone, C. ;

Sawyer, M. B. ;

Moore, M. J. ;

Miller, W. H., Jr. ;

Bagala, C. ;

Colombi, F. ;

Cagnazzo, C. ;

Gioeni, L. ;

Wang, E. ;

Huang, B. ;

Fly, K. D. ;

Leone, F. .

ANNALS OF ONCOLOGY, 2014, 25 (09) :1750-1755

[3]

[Anonymous], 2016, CURR PROTOC PHARM

[4]

[Anonymous], 2017, J Immunother Cancer

[5] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Yokoi, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

de Castro Carpeno, J. ;

Wadsworth, C. ;

Melillo, G. ;

Jiang, H. ;

Huang, Y. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929

[6] DCLK1 Marks a Morphologically Distinct Subpopulation of Cells With Stem Cell Properties in Preinvasive Pancreatic Cancer [J].

Bailey, Jennifer M. ;

Alsina, Janivette ;

Rasheed, Zeshaan A. ;

McAllister, Florencia M. ;

Fu, Ya-Yuan ;

Plentz, Ruben ;

Zhang, Hao ;

Pasricha, Pankaj J. ;

Bardeesy, Nabeel ;

Matsui, William ;

Maitra, Anirban ;

Leach, Steven D. .

GASTROENTEROLOGY, 2014, 146 (01) :245-256

[7] Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma [J].

Bailey, Peter ;

Chang, David K. ;

Forget, Marie-Andree ;

San Lucas, Francis A. ;

Alvarez, Hector A. ;

Haymaker, Cara ;

Chattopadhyay, Chandrani ;

Kim, Sun-Hee ;

Ekmekcioglu, Suhendan ;

Grimm, Elizabeth A. ;

Biankin, Andrew V. ;

Hwu, Patrick ;

Maitra, Anirban ;

Roszik, Jason .

SCIENTIFIC REPORTS, 2016, 6

[8] Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer [J].

Balachandran, Vinod P. ;

Luksza, Marta ;

Zhao, Julia N. ;

Makarov, Vladimir ;

Moral, John Alec ;

Remark, Romain ;

Herbst, Brian ;

Askan, Gokce ;

Bhanot, Umesh ;

Senbabaoglu, Yasin ;

Wells, Daniel K. ;

Cary, Charles Ian Ormsby ;

Grbovic-Huezo, Olivera ;

Attiyeh, Marc ;

Medina, Benjamin ;

Zhang, Jennifer ;

Loo, Jennifer ;

Saglimbeni, Joseph ;

Abu-Akeel, Mohsen ;

Zappasodi, Roberta ;

Riaz, Nadeem ;

Smoragiewicz, Martin ;

Kelley, Z. Larkin ;

Basturk, Olca ;

Goenen, Mithat ;

Levine, Arnold J. ;

Allen, Peter J. ;

Fearon, Douglas T. ;

Merad, Miriam ;

Gnjatic, Sacha ;

Iacobuzio-Donahue, Christine A. ;

Wolchok, Jedd D. ;

DeMatteo, Ronald P. ;

Chan, Timothy A. ;

Greenbaum, Benjamin D. ;

Merghoub, Taha ;

Leach, Steven D. .

NATURE, 2017, 551 (7681) :512-+

[9] Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer [J].

Balli, David ;

Rech, Andrew J. ;

Stanger, Ben Z. ;

Vonderheide, Robert H. .

CLINICAL CANCER RESEARCH, 2017, 23 (12) :3129-3138

[10] Tumor-Derived Granulocyte-Macrophage Colony-Stimulating Factor Regulates Myeloid Inflammation and T Cell Immunity in Pancreatic Cancer [J].

Bayne, Lauren J. ;

Beatty, Gregory L. ;

Jhala, Nirag ;

Clark, Carolyn E. ;

Rhim, Andrew D. ;

Stanger, Ben Z. ;

Vonderheide, Robert H. .

CANCER CELL, 2012, 21 (06) :822-835

← 1 2 3 4 5 6 7 8 9 10 →